Verona Pharma Insider Sold Shares Worth $2,303,773, According to a Recent SEC Filing
Does Verona Pharma (NASDAQ:VRNA) Have A Healthy Balance Sheet?
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Form 144 | Verona Pharma(VRNA.US) Officer Proposes to Sell 3.47 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Oct 18, $Verona Pharma(VRNA.US)$ Officer MARK HAHN intends to sell 100K shares of its common stock on Oct 18, with a total market value of approximately $3.47 million.
Form 144 | Verona Pharma(VRNA.US) Director Proposes to Sell 3.47 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Oct 18, $Verona Pharma(VRNA.US)$ Director DAVID ZACCARDELLI intends to sell 100K shares of its common stock on Oct 18, with a total market value of approximately $3.47 million.
US stocks anomaly | verona pharma continued to rise 3.6% before the market opened, with hopes of hitting another new high at the opening.
Great Wall Network October 15th | Verona Pharma (VRNA.US) continued to rise by 3.61% before the market opening, with hopes of reaching a new historical high at the opening. Recently, the company has received positive recommendations from many major banks: Joon Lee, an analyst from MyBank, maintains a "buy" rating for Verona Pharma with a target price of $38; Truist Securities has raised its target price from $38 to $44; Piper Sandler maintains a "buy" rating for the company, with a target price of $36. (Great Wall Network)